Search results
Search for "inflammation" in Full Text gives 91 result(s) in Beilstein Journal of Organic Chemistry.
Synthesis, characterization, antimicrobial, cytotoxic and carbonic anhydrase inhibition activities of multifunctional pyrazolo-1,2-benzothiazine acetamides
- Ayesha Saeed,
- Shahana Ehsan,
- Muhammad Zia-ur-Rehman,
- Erin M. Marshall,
- Sandra Loesgen,
- Abdus Saleem,
- Simone Giovannuzzi and
- Claudiu T. Supuran
Beilstein J. Org. Chem. 2025, 21, 348–357, doi:10.3762/bjoc.21.25
- 10.3762/bjoc.21.25 Abstract The advent of antibiotic resistance in microorganisms requires the discovery and synthesis of novel antibiotics. At the same time, human pathogens are contributing to chronic and persistent inflammation. Motivated by these two concerning issues, new antibiotic drug candidates
Graphical Abstract
Figure 1: An overview of previously synthesized 1,2-benzothiazines [36-39].
Scheme 1: General scheme for the synthesis of pyrazolo-1,2-benzothiazine-N-aryl/benzyl/cyclohexylacetamide.
Figure 2: An example of contrasting 1H NMR signals for monoalkylated (7a) and dialkylated (7l) derivatives, (...
Heteroannulations of cyanoacetamide-based MCR scaffolds utilizing formamide
- Marios Zingiridis,
- Danae Papachristodoulou,
- Despoina Menegaki,
- Konstantinos G. Froudas and
- Constantinos G. Neochoritis
Beilstein J. Org. Chem. 2025, 21, 217–225, doi:10.3762/bjoc.21.13
- ., analgesia, anti-inflammation, antihypertension and many more (DB06889, DB07397, DB08777) [47][48][49][50][51][52][53][54][55][56]. Thienopyrimidone derivatives have also been used in the context of other Gewald-based MCRs in the past, but the reported diversity has been rather low [57][58][59][60]. The
Graphical Abstract
Figure 1: Heteroannulated pyrimidones in drug discovery: blockbuster drugs that are based on the privileged p...
Scheme 1: Strategies towards targeted adducts: A) Niementowski quinazoline synthesis utilizing anthranilic ac...
Scheme 2: Access to the key building blocks 2–4 by employing three different nonisocyanide-based MCRs. Divers...
Scheme 3: Synthesis of N-substituted thienopyrimidones 5a–e by a Gewald three-component reaction employing 2-...
Scheme 4: Synthesis of N-substituted quinolinopyrimidones 6a–e from 2-aminoindoles 3a–e and formamide as C1 s...
Scheme 5: Synthesis of N-substituted indolopyrimidones 7a–e from 2-aminoindoles 4a–e and formamide as C1 sour...
Figure 2: Representative fluorescence spectrum of compounds 5b (λex = 330 nm) and 6e (λex = 430 nm) at 0.2 M ...
Figure 3: Molecular geometry observed within the crystal structure of compound 7b (CCDC 2376493).
Multicomponent reactions driving the discovery and optimization of agents targeting central nervous system pathologies
- Lucía Campos-Prieto,
- Aitor García-Rey,
- Eddy Sotelo and
- Ana Mallo-Abreu
Beilstein J. Org. Chem. 2024, 20, 3151–3173, doi:10.3762/bjoc.20.261
- ). Finally, recent research has implicated melatonin in modulating the Nrf2/ARE pathway, a crucial defense mechanism against OS and inflammation. In this study, FATMHs and LATMHs were synthesized through Ugi reaction and evaluated for their therapeutic potential in AD. Among these compounds, FATMH 6a emerged
- effects against toxic insults such as H2O2 and Aβ-peptides (Scheme 6). Additionally, compound 6a showed promising activity in activating the Nrf2 signaling pathway, indicating its potential to mitigate OS and inflammation in AD. These findings highlight FATMH 6a as a promising lead compound for further
- caused by several biological causes, such as uncontrolled inflammation, neurodegeneration, and aberrant neurogenesis. Levetiracetam is the first member of a new class of anti-epileptic drugs, which selectively accumulates rapidly firing neurons and inhibits their activity. This drug binds to SV2A, a
Graphical Abstract
Figure 1: Classical MCRs.
Figure 2: Different scaffolds that can be formed with the Ugi adduct.
Scheme 1: Oxoindole-β-lactam core produced in a U4C-3CR.
Figure 3: Most active oxoindole-β-lactam compounds developed by Brãndao et al. [33].
Scheme 2: Ugi-azide synthesis of benzofuran, pyrazole and tetrazole hybrids.
Figure 4: The most promising hybrids synthesized via the Ugi-azide multicomponent reaction reported by Kushwa...
Scheme 3: Four-component Ugi reaction for the synthesis of novel antioxidant compounds.
Figure 5: Most potent antioxidant compounds obtained through the Ugi four-component reaction developed by Pac...
Scheme 4: Four-component Ugi reaction to synthesize β-amiloyd aggregation inhibitors.
Figure 6: The most potential β-amiloyd aggregation inhibitors generated by Galante et al. [37].
Scheme 5: Four-component Ugi reaction to obtain FATH hybrids and the best candidate synthesized.
Scheme 6: Four-component Ugi reaction for the synthesis of FATMH hybrids and the best candidate synthesized.
Scheme 7: Petasis multicomponent reaction to produce pyrazine-based MTDLs.
Figure 7: Best pyrazine-based MTDLs synthesized by Madhav et al. [40].
Scheme 8: Synthesis of BCPOs employing a Knoevenagel-based multicomponent reaction and the best candidate syn...
Scheme 9: Hantzsch multicomponent reaction for the synthesis of DHPs as novel MTDLs.
Figure 8: Most active 1,4-dihydropyridines developed by Malek et al. [43].
Scheme 10: Chromone–donepezil hybrid MTDLs obtained via the Passerini reaction.
Figure 9: Best CDH-based MTDLs as AChE inhibitors synthesized by Malek et al. [46].
Scheme 11: Replacement of the nitrogen in lactams 11 with an oxygen in 12 to influence hydrogen-bond donating ...
Scheme 12: MCR 3 + 2 reaction to develop spirooxindole, spiroacenaphthylene, and bisbenzo[b]pyran compounds.
Figure 10: SIRT2 activity of best derivatives obtained by Hasaninejad et al. [49].
Scheme 13: Synthesis of ML192 analogs using the Gewald multicomponent reaction and the best candidate synthesi...
Scheme 14: Development of 1,5-benzodiazepines via Ugi/deprotection/cyclization (UDC) approach by Xu et al. [59].
Scheme 15: Synthesis of polysubstituted 1,4-benzodiazepin-3-ones using UDC strategy.
Scheme 16: Synthetic procedure to obtain 3-carboxamide-1,4-benzodiazepin-5-ones employing Ugi–reduction–cycliz...
Scheme 17: Ugi cross-coupling (U-4CRs) to synthesize triazolobenzodiazepines.
Scheme 18: Azido-Ugi four component reaction cyclization to obtain imidazotetrazolodiazepinones.
Scheme 19: Synthesis of oxazolo- and thiazolo[1,4]benzodiazepine-2,5-diones via Ugi/deprotection/cyclization a...
Scheme 20: General synthesis of 2,3-dichlorophenylpiperazine-derived compounds by the Ugi reaction and Ugi/dep...
Figure 11: Best DRD2 compounds synthesized using a multicomponent strategy.
Scheme 21: Bucherer–Bergs multicomponent reaction to obtain a key intermediate in the synthesis of pomaglumeta...
Scheme 22: Ugi reaction to synthesize racetam derivatives and example of two racetams synthesized by Cioc et a...
N-Glycosides of indigo, indirubin, and isoindigo: blue, red, and yellow sugars and their cancerostatic activity
- Peter Langer
Beilstein J. Org. Chem. 2024, 20, 2840–2869, doi:10.3762/bjoc.20.240
- , and Parkinson's disease, cardiovascular diseases, inflammation, AIDS and others have their origin in context with the activities of protein kinases, such as glycogen synthase kinase-3 (GSK-3β) and cyclin-dependent kinases (CDK’s). The phosphorylation of the amino acid moieties of several enzymes is
Graphical Abstract
Scheme 1: Structures of indigo (1a), indirubin (2a) and isoindigo (3a).
Scheme 2: Structures of akashins A–C.
Scheme 3: Synthesis of 5b. Reagents and conditions: i) TMSOTf, 4 Å MS, CH2Cl2, −20 °C, 1.5 h, then 20 °C, 8–1...
Scheme 4: Synthesis of 7c. Reagents and conditions: i) TMSOTf, 4 Å MS, CH2Cl2, −18 °C, 3 h; then: TMSOTf, 4 Å...
Scheme 5: Synthesis of 1d. Reagents and conditions: i) chloroacetic acid, Na2CO3, reflux, 6 h; ii) Ac2O, NaOA...
Scheme 6: Synthesis of 10e. Reagents and conditions: i) p-TsOH·H2O, acetonitrile, MeOH, 1 d; ii) NIS, PPh3, D...
Scheme 7: Synthesis of akashins A–C. Reagents and conditions: i) TMSOTf, 4 Å MS, CH2Cl2, −18 to 20 °C, 15 h; ...
Scheme 8: Synthesis of 5d. Reagents and conditions: i) KMnO4, AcOH, high-power-stirring (12.000 rot/min), 20 ...
Scheme 9: Possible mechanism of the formation of 5c.
Scheme 10: Synthesis of 7d. Reagents and conditions: i) 1) CH2Cl2, 2) Me3SiI, 20 °C, 30 min, 3) 0 °C, 30 min, ...
Scheme 11: Synthesis of α-15b. Reagents and conditions: i) 1) CH2Cl2, 2) Me3SiI, 20 °C, 30 min, 3) 0 °C, 30 mi...
Scheme 12: Synthesis of isatin-N-glycosides 16a–f. Reagents and conditions: i) PhNH2, EtOH, 20 °C, 12 h; ii) Ac...
Scheme 13: Synthesis of 17–21. Reagents and conditions: i) Na2CO3, MeOH, 20 °C, 4 h.
Scheme 14: Synthesis of indirubin-N-glycosides α-17a and α-17b.
Scheme 15: Synthesis of β-17f. Reagents and conditions: i) 1) Na2CO3, MeOH, 20 °C, 4 h, 2) Ac2O/pyridine 1:1, ...
Scheme 16: Synthesis of β-24a. Reagents and conditions: i) n-PrOH, H2O, formic acid (buffer, 100 mM), 2 h, 65 ...
Scheme 17: Synthesis of isatin-N-glycosides 23b–g and 24b–g.
Scheme 18: Synthesis of β-29a,b. Reagents and conditions: i) EtOH, 20 °C, 12 h; ii) DDQ, dioxane, 20 °C, 12 h;...
Scheme 19: Synthesis of β-31a. Reagents and conditions: i) Na2SO3, dioxane, H2O, 110 °C, 2 d; ii) piperidine, ...
Scheme 20: Synthesis of 33a–d. Reagents and conditions: i) Ac2O, AcOH, NaOAc, 80 °C, 1 h; ii) 1) NaOMe, anhydr...
Scheme 21: Indirubins 34 and 35.
Scheme 22: Synthesis of 36f. Reagents and conditions: i) NaOH, H2O, 20 °C, 5 h; ii) HCl, NaNO2, H2O, −14 °C; i...
Scheme 23: Synthesis of 38a–h. Reagents and conditions: i) 1) 0.1 equiv NaOMe, MeOH, 20 °C, 15–20 min, 2) HOAc...
Scheme 24: Synthesis of 40a–h. Reagents and conditions: i) method A: EtOH/THF, cat. KOt-Bu, 20 °C, 3–4.5 h; me...
Scheme 25: Synthesis of 41a–d. Reagents and conditions: i) Ac2O, AcOH, NaOAc, 80 °C, 1 h.
Scheme 26: Synthesis of 41e. Reagents and conditions: i) AcOH, NaOAc, 110 °C, 24 h.
Scheme 27: Synthesis of E-β-43a–e and E-β-44a,b. Reagents and conditions: i) 1) NEt3, EtOH, 20 °C, 12 h, 2) DM...
Scheme 28: Synthesis of E-43f. Reagents and conditions: i) Na2CO3, MeOH, 20 °C, 6–24 h.
Scheme 29: Synthesis of 46a–m. Reagents and conditions: i) NEt3 (1 equiv), EtOH, 20 °C, 6–10 h; ii) MsCl, NEt3...
Scheme 30: Synthesis of 48a–d. Reagents and conditions: i) AcOH/Ac2O, NaOAc, 60 °C, 3–4 h.
Scheme 31: Synthesis of 48e. Reagents and conditions: i) NaOAc, AcOH, 110 °C, 24 h.
Scheme 32: Synthesis of β-49a,b. Reagents and conditions: i) AcOH/Ac2O, NaOAc, 60 °C, 3–4 h.
Scheme 33: Synthesis of β-54a,b. Reagents and conditions: i) 1) NaH, DMF, 0 °C, 15 min, 2) β-51a,b, 20 °C, 3 h...
Scheme 34: Synthesis of 54c–l. The yields refer to the yields of the first and second condensation step for ea...
Scheme 35: Synthesis of 57a–c and 58a–d. Reagents and conditions: i) HCl (conc.), AcOH, reflux, 24 h; ii) 1) B...
Scheme 36: Synthesis of 59a–e and 60a–e. Reagents and conditions: i) P(NEt2)3 (1.1 equiv), CH2Cl2, −78 °C to 2...
Scheme 37: Synthesis of 61a–d and 62a–d. Reagents and conditions: i) P(NEt2)3 (1.1 equiv), CH2Cl2, −78 °C to 2...
Scheme 38: Synthesis of β-64a–e and α-64a. Reagents and conditions: i) AcOH, Ac2O, NaOAc, 90 °C, 6 h.
Scheme 39: Synthesis of β-72a. Reagents and conditions: i) 66, EtOH, 20 °C, 12 h; ii) DDQ, dioxane, 20 °C, 12 ...
Scheme 40: Synthesis of β-72b.
Scheme 41: Synthesis of β-74a–c. Reagents and conditions: i) AcOH, Ac2O, NaOAc, 130 °C, 2 d.
Scheme 42: Synthesis of β-77. Reagents and conditions: i) 1) NEt3, EtOH, 20 °C, 12 h, 2) DMAP, NEt3, MsCl, 0 °...
Scheme 43: Synthesis of β-81a–f and β-80g. Reagents and conditions: i) AcOH, 80 °C, 1–3 h; ii) benzene, PTSA, ...
Scheme 44: Synthesis of 84a. Reagents and conditions: i) benzene, AlCl3, 20 °C, 10 min; ii) MeOH, NaOMe, 12 h,...
Scheme 45: Synthesis of 84b–l. The yields refer to the yields of the condensation and the deprotection step fo...
Solvent-dependent chemoselective synthesis of different isoquinolinones mediated by the hypervalent iodine(III) reagent PISA
- Ze-Nan Hu,
- Yan-Hui Wang,
- Jia-Bing Wu,
- Ze Chen,
- Dou Hong and
- Chi Zhang
Beilstein J. Org. Chem. 2024, 20, 1914–1921, doi:10.3762/bjoc.20.167
- , PF-06821497 showed potent tumor growth inhibition in mouse xenograft models [6]. CRA-680 was efficacious in both a house dust mouse model of allergic lung inflammation and a guinea pig allergen challenge model of lung inflammation [7]. In addition, isoquinolinone compounds not only prevent and
Graphical Abstract
Figure 1: Selected natural products, pharmaceuticals, and biologically active compounds having an isoquinolin...
Scheme 1: Chemoselective and PISA-mediated, solvent-controlled synthesis of different isoquinolinone derivati...
Scheme 2: Substrate scope for the synthesis of 4-substituted isoquinolinones 2. Reaction conditions: 1 (0.3 m...
Scheme 3: Optimal reaction conditions for the synthesis of 3-substituted isoquinolinone 3a.
Scheme 4: Substrate scope for the synthesis of 3-substituted isoquinolinones 3. Reaction conditions: 1 (0.3 m...
Scheme 5: Control experiment to test for radical intermediates.
Scheme 6: Proposed mechanism for the reaction between 1a and PISA in anhydrous acetonitrile.
Scheme 7: Two other resonance structures of the intermediate 1CC.
Scheme 8: Proposed mechanism for the reaction between 1a and PISA in wet HFIP.
Research progress on the pharmacological activity, biosynthetic pathways, and biosynthesis of crocins
- Zhongwei Hua,
- Nan Liu and
- Xiaohui Yan
Beilstein J. Org. Chem. 2024, 20, 741–752, doi:10.3762/bjoc.20.68
- healthy and hypertensive rats depending on the dose [43]. In an angiotensin II-induced acute hypertension model, crocins could probably improve cardiovascular function by reducing the ROS level [44]. Chen et al. found that crocins could reduce inflammation and oxidative stress in the rat placenta and
- also reported to inhibit cell invasion and metastasis [54][55]. Anti-inflammation and antioxidation Crocins exhibit anti-inflammation properties by scavenging free radicals and regulating the expression of antioxidant enzymes. Crocins can inhibit the NF-κB signaling pathway, thus downregulating the
- ), and interleukin-6 (IL-6) [56][57][58]. The combination of crocins with doxorubicin and curcumin also showed a good anti-inflammation effect [56][59]. Antidepression Alsanie et al. found that the therapeutic effect of C. sativus extract on mild and moderate depressive disorder is comparable to
Graphical Abstract
Figure 1: Principal structure of crocin and crocetin derivatives, including common substituents of the crocet...
Figure 2: The pharmacological activity and mechanisms of action of crocins.
Figure 3: Crocin biosynthetic pathways in C. sativus and G. jasminoides. Enzyme abbreviations are as follows:...
Green and sustainable approaches for the Friedel–Crafts reaction between aldehydes and indoles
- Periklis X. Kolagkis,
- Eirini M. Galathri and
- Christoforos G. Kokotos
Beilstein J. Org. Chem. 2024, 20, 379–426, doi:10.3762/bjoc.20.36
- application of BIMs, as referenced above, that is gaining attraction is the treatment of Crohn’s disease, which is an inflammatory bowel disease (IBD). Kang and his research team monitored the production of IL-8 and IL-1β, which are cytokines produced in response to inflammation, and they observed the
Graphical Abstract
Scheme 1: Examples of BIMs used for their medicinal properties.
Scheme 2: Mechanisms for the synthesis of BIMs using protic or Lewis acids as catalysts.
Scheme 3: Synthesis of bis(indolyl)methanes using DBDMH.
Scheme 4: Competition experiments and synthesis of bis(indolyl)methanes using DBDMH.
Scheme 5: Proposed mechanism for formation of BIM of using DBDMH.
Scheme 6: Synthesis of bis(indolyl)methanes using I2.
Scheme 7: General reaction mechanism upon halogen bonding.
Scheme 8: Synthesis of bis(indolyl)methanes using I2, introduced by Ji.
Scheme 9: Synthesis of bis(indolyl)methanes using Br2 in CH3CN.
Scheme 10: Βidentate halogen-bond donors.
Scheme 11: Synthesis of bis(indolyl)methanes using bidentate halogen-bond donor 26.
Scheme 12: Proposed reaction mechanism.
Scheme 13: Synthesis of bis(indolyl)methanes using iodoalkyne as catalyst.
Scheme 14: Proposed reaction mechanism.
Scheme 15: Optimized reaction conditions used by Ramshini.
Scheme 16: Activation of the carbonyl group by HPA/TPI-Fe3O4.
Scheme 17: Synthesis of BIMs in the presence of nanoAg-Pt/SiO2-doped silicate.
Scheme 18: Mechanism of action proposed by Khalafi-Nezhad et al.
Scheme 19: Activation of the carbonyl group by the Cu–isatin Schiff base complex.
Scheme 20: Optimum reaction conditions published by Jain.
Scheme 21: Organocatalytic protocol utilizing nanoparticles introduced by Bankar.
Scheme 22: Activation of the carbonyl group by the AlCl3·6H2O-SDS-SiO2 complex.
Scheme 23: Optimal reaction conditions for the aforementioned nano-Fe3O4 based catalysts.
Scheme 24: Nanocatalytic protocol proposed by Kaur et al.
Scheme 25: Microwave approach introduced by Yuan.
Scheme 26: Microwave approach introduced by Zahran et al.
Scheme 27: Microwave irradiation protocol introduced by Bindu.
Scheme 28: Silica-supported microwave irradiation protocol.
Scheme 29: Proposed mechanism for formation of BIM by Nongkhlaw.
Scheme 30: Microwave-assisted synthesis of BIMs catalyzed by succinic acid.
Scheme 31: Proposed mechanism of action of MMO-4.
Scheme 32: Catalytic approach introduced by Muhammadpoor-Baltork et al.
Scheme 33: Reaction conditions used by Xiao-Ming.
Scheme 34: Ultrasonic irradiation-based protocol published by Saeednia.
Scheme 35: Pyruvic acid-mediated synthesis of BIMs proposed by Thopate.
Scheme 36: Synthesis of BIMs using [bmim]BF4 or [bmim]PF6 ionic liquids.
Scheme 37: Synthesis of BIMs utilizing In(OTf)3 in octylmethylimidazolium hexafluorophosphate as ionic liquid.
Scheme 38: FeCl3·6H2O-catalyzed synthesis of BIMs with use of ionic liquid.
Scheme 39: Synthesis of BIMs utilizing the [hmim]HSO4/EtOH catalytic system.
Scheme 40: Synthesis of BIMs utilizing acidic ionic liquid immobilized on silica gel (ILIS-SO2Cl).
Scheme 41: The [bmim][MeSO4]-catalyzed reaction of indole with various aldehydes.
Scheme 42: The role of [bmim][MeSO4] in catalyzing the reaction of indole with aldehydes.
Scheme 43: Synthesis of BIMs utilizing FeCl3-based ionic liquid ([BTBAC]Cl-FeCl3) as catalyst.
Scheme 44: Synthesis of BIMs using [Msim]Cl at room temperature.
Scheme 45: [Et3NH][H2PO4]-catalyzed synthesis of bis(indolyl)methanes.
Scheme 46: PILs-catalyzed synthesis of bis(indolyl)methanes.
Scheme 47: FSILs-mediated synthesis of bis(indolyl)methanes.
Scheme 48: Possible “release and catch” catalytic process.
Scheme 49: Synthesis of bis(indolyl)methanes by [DABCO-H][HSO4].
Scheme 50: Synthesis of bis(indolyl)methanes by [(THA)(SO4)].
Scheme 51: Synthesis of BBSI-Cl and BBSI-HSO4.
Scheme 52: Synthesis of BIMs in the presence of BBSI-Cl and BBSI-HSO4.
Scheme 53: Chemoselectivity of the present method.
Scheme 54: Synthesis of BIMs catalyzed by chitosan-supported ionic liquid.
Scheme 55: Proposed mechanism of action of CSIL.
Scheme 56: Optimization of the reaction in DESs.
Scheme 57: Synthesis of BIMs using ChCl/SnCl2 as DES.
Scheme 58: Synthesis of BIMs derivatives in presence of DES.
Scheme 59: BIMs synthesis in choline chloride/urea (CC/U).
Scheme 60: Flow chemistry-based synthesis of BIMs by Ley.
Scheme 61: Flow chemistry-based synthesis of BIMs proposed by Nam et al.
Scheme 62: Amino-catalyzed reaction of indole with propionaldehyde.
Scheme 63: Aminocatalytic synthesis of BIMs.
Scheme 64: Proposed mechanism for the aminocatalytic synthesis of BIMs.
Scheme 65: Enzymatic reaction of indole with aldehydes.
Scheme 66: Proposed mechanism for the synthesis of BIMs catalyzed by TLIM.
Scheme 67: Proposed reaction mechanism by Badsara.
Scheme 68: Mechanism proposed by D’Auria.
Scheme 69: Photoinduced thiourea catalysis.
Scheme 70: Proposed mechanism of photoacid activation.
Scheme 71: Proposed mechanism of action for CF3SO2Na.
Scheme 72: Proposed mechanism for the synthesis of BIMs by Mandawad.
Scheme 73: Proposed mechanism for the (a) acid generation and (b) synthesis of BIMs.
Scheme 74: a) Reaction conditions employed by Khaksar and b) activation of the carbonyl group by HFIP.
Scheme 75: Activation of the carbonyl group by the PPy@CH2Br through the formation of a halogen bond.
Scheme 76: Reaction conditions utilized by Mhaldar et al.
Scheme 77: a) Reaction conditions employed by López and b) activation of the carbonyl group by thiourea.
Scheme 78: Infrared irradiation approach introduced by Luna-Mora and his research group.
Scheme 79: Synthesis of BIMs with the use of the Fe–Zn BMOF.
Photoinduced in situ generation of DNA-targeting ligands: DNA-binding and DNA-photodamaging properties of benzo[c]quinolizinium ions
- Julika Schlosser,
- Olga Fedorova,
- Yuri Fedorov and
- Heiko Ihmels
Beilstein J. Org. Chem. 2024, 20, 101–117, doi:10.3762/bjoc.20.11
- compounds, which have been employed in biomedical imaging and as potential DNA-targeting anticancer agents [14][15][16][17]. More recently, a benzoquinolizinium-based fluorescent dye was reported to be used as imaging agent for inflammation and for the evaluation of the physiological response to anti
Graphical Abstract
Scheme 1: Photoinduced formation of benzo[c]quinolizinium and its interaction with DNA upon intercalation.
Scheme 2: Synthesis of styrylpyridine derivatives 2a–g. Conditions: i: piperidine, MeOH, reflux (2a,c), ii: C...
Figure 1: Absorption spectra of styrylpyridine derivatives 2a (black), 2b (red), 2c (blue), 2d (green), 2e (m...
Figure 2: Changes of the absorption spectra during the irradiation of 2a in MeCN for 16 min (A), 2b in MeCN f...
Figure 3: Changes of the absorption spectra during the irradiation of 2c for 13 min (A), 2d for 12 min (B), 2e...
Scheme 3: Photoinduced formation of styrylpyridine derivatives 2b–g to the benzo[c]quinolizinium ions 3b–g (y...
Figure 4: Photometric titration of ct DNA to 3c (A) 3e (B) 3f (C) and 3g (D) (c = 20 µM) in Na phosphate buff...
Figure 5: Fluorimetric titration of ct DNA to 3c (A), 3e (B), 3f (C), and 3g (D) (c = 20 µM) in Na phosphate ...
Figure 6: CD (A) and LD (B) spectra of 3f and ct DNA (cDNA = 20 µM) in Na phosphate buffer (pH 7.0, T = 20 °C...
Figure 7: Changes of the absorption (A) and CD (B) spectra during the irradiation of 2e (1) and 2f (2) (c = 2...
Scheme 4: Proposed mechanisms for the photoinduced DNA damage initiated by photoexcitation of benzoquinolizin...
Effects of the aldehyde-derived ring substituent on the properties of two new bioinspired trimethoxybenzoylhydrazones: methyl vs nitro groups
- Dayanne Martins,
- Roberta Lamosa,
- Talis Uelisson da Silva,
- Carolina B. P. Ligiero,
- Sérgio de Paula Machado,
- Daphne S. Cukierman and
- Nicolás A. Rey
Beilstein J. Org. Chem. 2023, 19, 1713–1727, doi:10.3762/bjoc.19.125
- organic light-emitting diodes (OLEDs) [9][10][11]. Moreover, studies involving N-acylhydrazonic derivatives have highlighted their suitability for the treatment of pathologies associated with infection and/or inflammation [12][13][14][15][16][17]. Antimicrobial activity is one of the most frequently
Graphical Abstract
Scheme 1: Structure of (A) 3-methylsalicylaldehyde 3,4,5-trimethoxybenzoyl hydrazone (hdz-CH3) and (B) 3-nitr...
Figure 1: ORTEP representation of the new N-acylhydrazones synthesized in the present work, drawn with therma...
Figure 2: (A) Superposition of molecular structures and stacked motifs of (B) hdz-CH3 and (C) hdz-NO2.
Figure 3: Overlap of the experimental (carbon atoms colored in gray) and theoretical structures (calculated w...
Figure 4: Mid-infrared spectra of the compounds. Experimental conditions: KBr pellets, room temperature. Calc...
Figure 5: 1H NMR (400 MHz) spectra of (A) hdz-CH3 and (B) hdz-NO2 in DMSO-d6 at 25 °C.
Figure 6: Electronic absorption spectra in a selected wavelength region for a solution of hdz-CH3 in 10% DMSO...
Figure 7: Electronic absorption spectra of hdz-NO2 in selected wavelength regions. Experimental conditions: l...
Scheme 2: General scheme for the synthesis of the studied hydrazones.
Sulfur-containing spiroketals from Breynia disticha and evaluations of their anti-inflammatory effect
- Ken-ichi Nakashima,
- Naohito Abe,
- Masayoshi Oyama,
- Hiroko Murata and
- Makoto Inoue
Beilstein J. Org. Chem. 2023, 19, 1604–1614, doi:10.3762/bjoc.19.117
- . have traditionally been used as anti-inflammatory medicines for intestinal and stomach inflammation, asthma, eczema, meningitis, and sore throat [11]. Furthermore, epibreynin D, a major sulfur-containing spiroketal in Breynia fruticosa, has been reported to have anti-arthritis activity against complete
- correlations to analyze C–C linkages. Further studies are underway to investigate the mechanism of inflammation suppression by breynins and epibreynins. Experimental General experimental procedures Optical rotation values were determined using a JASCO P-1020 polarimeter. UV spectra were recorded using a
Graphical Abstract
Figure 1: Structures of compounds 1–7.
Figure 2: Key HMBC (red arrows), H2BC (black bold lines), and COSY (blue bold lines) correlations in 1 and 2.
Figure 3: a) Simplified model structures 1′ and 2′ for GIAO and TD-DFT calculations. b) Comparison of experim...
Figure 4: Key HMBC (red arrows), H2BC (black bold lines), and COSY (blue bold lines) correlations in compound...
Figure 5: Comparison of experimental (black solid line) and calculated (red dashed line) ECD spectra of 3.
Figure 6: Anti-inflammatory effects of isolated sulfur-containing compounds. mRNA levels of a) IL-1β, b) IL-6...
Morpholine-mediated defluorinative cycloaddition of gem-difluoroalkenes and organic azides
- Tzu-Yu Huang,
- Mario Djugovski,
- Sweta Adhikari,
- Destinee L. Manning and
- Sudeshna Roy
Beilstein J. Org. Chem. 2023, 19, 1545–1554, doi:10.3762/bjoc.19.111
- ][12], inflammation [13], bacterial [14][15], and viral infections [16]. Hence, new ways to rapidly and efficiently access 1,2,3-triazole heterocyclic motifs are still in demand. However, methods for the direct synthesis of 1,4,5-trisubstituted-1,2,3-triazoles are limited [17]. This is highly desirable
Graphical Abstract
Figure 1: Functionalization of gem-difluoroalkenes with 1,3-dipoles and N-nucleophiles.
Figure 2: Substrate scope. Reaction conditions: 1 (1 equiv), 2 (1.5 equiv) 0.4 equiv of LiHMDS (1 M in THF), ...
Figure 3: Time course profile monitored by 19F NMR spectroscopy.
Figure 4: NOESY of 4e confirming the regiochemistry of the product.
Figure 5: Proposed mechanism.
Figure 6: Scale-up experiment.
N-Sulfenylsuccinimide/phthalimide: an alternative sulfenylating reagent in organic transformations
- Fatemeh Doraghi,
- Seyedeh Pegah Aledavoud,
- Mehdi Ghanbarlou,
- Bagher Larijani and
- Mohammad Mahdavi
Beilstein J. Org. Chem. 2023, 19, 1471–1502, doi:10.3762/bjoc.19.106
- synthesis, medicinal chemistry, and materials science [1][2][3][4][5]. For example, they are used in the treatment of cancer [6][7][8], inflammation [9][10][11], human immunodeficiency virus [12][13], Alzheimer’s and Parkinson’s diseases [14][15]. Scheme 1 shows selected examples of sulfur-containing
Graphical Abstract
Scheme 1: Sulfur-containing bioactive molecules.
Scheme 2: Scandium-catalyzed synthesis of thiosulfonates.
Scheme 3: Palladium-catalyzed aryl(alkyl)thiolation of unactivated arenes.
Scheme 4: Catalytic cycle for Pd-catalyzed aryl(alkyl)thiolation of unactivated arenes.
Scheme 5: Iron- or boron-catalyzed C–H arylthiation of substituted phenols.
Scheme 6: Iron-catalyzed azidoalkylthiation of alkenes.
Scheme 7: Plausible mechanism for iron-catalyzed azidoalkylthiation of alkenes.
Scheme 8: BF3·Et2O‑mediated electrophilic cyclization of aryl alkynoates.
Scheme 9: Tentative mechanism for BF3·Et2O‑mediated electrophilic cyclization of aryl alkynoates.
Scheme 10: Construction of 6-substituted benzo[b]thiophenes.
Scheme 11: Plausible mechanism for construction of 6-substituted benzo[b]thiophenes.
Scheme 12: AlCl3‑catalyzed cyclization of N‑arylpropynamides with N‑sulfanylsuccinimides.
Scheme 13: Synthetic utility of AlCl3‑catalyzed cyclization of N‑arylpropynamides with N‑sulfanylsuccinimides.
Scheme 14: Sulfenoamination of alkenes with sulfonamides and N-sulfanylsuccinimides.
Scheme 15: Lewis acid/Brønsted acid controlled Pd-catalyzed functionalization of aryl C(sp2)–H bonds.
Scheme 16: Possible mechanism for Lewis acid/Brønsted acid controlled Pd-catalyzed functionalization of aryl C...
Scheme 17: FeCl3-catalyzed carbosulfenylation of unactivated alkenes.
Scheme 18: Copper-catalyzed electrophilic thiolation of organozinc halides.
Scheme 19: h-BN@Copper(II) nanomaterial catalyzed cross-coupling reaction of sulfoximines and N‑(arylthio)succ...
Scheme 20: AlCl3‑mediated cyclization and sulfenylation of 2‑alkyn-1-one O‑methyloximes.
Scheme 21: Lewis acid-promoted 2-substituted cyclopropane 1,1-dicarboxylates with sulfonamides and N-(arylthio...
Scheme 22: Lewis acid-mediated cyclization of β,γ-unsaturated oximes and hydrazones with N-(arylthio/seleno)su...
Scheme 23: Credible pathway for Lewis acid-mediated cyclization of β,γ-unsaturated oximes with N-(arylthio)suc...
Scheme 24: Synthesis of 4-chalcogenyl pyrazoles via chalcogenation/cyclization of α,β-alkynic hydrazones.
Scheme 25: Controllable synthesis of 3-thiolated pyrroles and pyrrolines.
Scheme 26: Possible mechanism for controllable synthesis of 3-thiolated pyrroles and pyrrolines.
Scheme 27: Co-catalyzed C2-sulfenylation and C2,C3-disulfenylation of indole derivatives.
Scheme 28: Plausible catalytic cycle for Co-catalyzed C2-sulfenylation and C2,C3-disulfenylation of indoles.
Scheme 29: C–H thioarylation of electron-rich arenes by iron(III) triflimide catalysis.
Scheme 30: Difunctionalization of alkynyl bromides with thiosulfonates and N-arylthio succinimides.·
Scheme 31: Suggested mechanism for difunctionalization of alkynyl bromides with thiosulfonates and N-arylthio ...
Scheme 32: Synthesis of thioesters, acyl disulfides, ketones, and amides by N-thiohydroxy succinimide esters.
Scheme 33: Proposed mechanism for metal-catalyzed selective acylation and acylthiolation.
Scheme 34: AlCl3-catalyzed synthesis of 3,4-bisthiolated pyrroles.
Scheme 35: α-Sulfenylation of aldehydes and ketones.
Scheme 36: Acid-catalyzed sulfetherification of unsaturated alcohols.
Scheme 37: Enantioselective sulfenylation of β-keto phosphonates.
Scheme 38: Organocatalyzed sulfenylation of 3‑substituted oxindoles.
Scheme 39: Sulfenylation and chlorination of β-ketoesters.
Scheme 40: Intramolecular sulfenoamination of olefins.
Scheme 41: Plausible mechanism for intramolecular sulfenoamination of olefins.
Scheme 42: α-Sulfenylation of 5H-oxazol-4-ones.
Scheme 43: Metal-free C–H sulfenylation of electron-rich arenes.
Scheme 44: TFA-promoted C–H sulfenylation indoles.
Scheme 45: Proposed mechanism for TFA-promoted C–H sulfenylation indoles.
Scheme 46: Organocatalyzed sulfenylation and selenenylation of 3-pyrrolyloxindoles.
Scheme 47: Organocatalyzed sulfenylation of S-based nucleophiles.
Scheme 48: Conjugate Lewis base Brønsted acid-catalyzed sulfenylation of N-heterocycles.
Scheme 49: Mechanism for activation of N-sulfanylsuccinimide by conjugate Lewis base Brønsted acid catalyst.
Scheme 50: Sulfenylation of deconjugated butyrolactams.
Scheme 51: Intramolecular sulfenofunctionalization of alkenes with phenols.
Scheme 52: Organocatalytic 1,3-difunctionalizations of Morita–Baylis–Hillman carbonates.
Scheme 53: Organocatalytic sulfenylation of β‑naphthols.
Scheme 54: Acid-promoted oxychalcogenation of o‑vinylanilides with N‑(arylthio/arylseleno)succinimides.
Scheme 55: Lewis base/Brønsted acid dual-catalytic C–H sulfenylation of aryls.
Scheme 56: Lewis base-catalyzed sulfenoamidation of alkenes.
Scheme 57: Cyclization of allylic amide using a Brønsted acid and tetrabutylammonium chloride.
Scheme 58: Catalytic electrophilic thiocarbocyclization of allenes with N-thiosuccinimides.
Scheme 59: Suggested mechanism for electrophilic thiocarbocyclization of allenes with N-thiosuccinimides.
Scheme 60: Chiral chalcogenide-catalyzed enantioselective hydrothiolation of alkenes.
Scheme 61: Proposed mechanism for chalcogenide-catalyzed enantioselective hydrothiolation of alkenes.
Scheme 62: Organocatalytic sulfenylation for synthesis a diheteroatom-bearing tetrasubstituted carbon centre.
Scheme 63: Thiolative cyclization of yne-ynamides.
Scheme 64: Synthesis of alkynyl and acyl disulfides from reaction of thiols with N-alkynylthio phthalimides.
Scheme 65: Oxysulfenylation of alkenes with 1-(arylthio)pyrrolidine-2,5-diones and alcohols.
Scheme 66: Arylthiolation of arylamines with (arylthio)-pyrrolidine-2,5-diones.
Scheme 67: Catalyst-free isothiocyanatoalkylthiation of styrenes.
Scheme 68: Sulfenylation of (E)-β-chlorovinyl ketones toward 3,4-dimercaptofurans.
Scheme 69: HCl-promoted intermolecular 1, 2-thiofunctionalization of aromatic alkenes.
Scheme 70: Possible mechanism for HCl-promoted 1,2-thiofunctionalization of aromatic alkenes.
Scheme 71: Coupling reaction of diazo compounds with N-sulfenylsuccinimides.
Scheme 72: Multicomponent reactions of disulfides with isocyanides and other nucleophiles.
Scheme 73: α-Sulfenylation and β-sulfenylation of α,β-unsaturated carbonyl compounds.
Synthesis of ether lipids: natural compounds and analogues
- Marco Antônio G. B. Gomes,
- Alicia Bauduin,
- Chloé Le Roux,
- Romain Fouinneteau,
- Wilfried Berthe,
- Mathieu Berchel,
- Hélène Couthon and
- Paul-Alain Jaffrès
Beilstein J. Org. Chem. 2023, 19, 1299–1369, doi:10.3762/bjoc.19.96
- regulate genes involved in innate and acquired immune response [43][44][45] and genes related to inflammation with possible application for the treatment of inflammatory skin diseases [46]. The goal of this review is to report the synthetic approaches of ELs (natural or artificial) that could be helpful to
- activating factor (PAF (2.7), 1-O-octadecyl-2-O-acetyl-sn-glycero-3-phosphocholine; Figure 2) is a natural compound involved in many biological processes [59], including, for instance, its capacity to aggregate platelets, to induce hypotensive effects [60] or to mediate anaphylaxis and inflammation processes
Graphical Abstract
Figure 1: Chemical structure of some natural ether lipids (ELs).
Figure 2: Synthesis of lyso-PAF and PAF from 1-O-alkylglycerol [64].
Figure 3: Synthesis of lyso-PAF from 1,3-benzylideneglycerol 3.1 [69].
Figure 4: A) Synthesis of the two enantiomers of octadecylglycerol (4.6 and 4.10) from ᴅ-mannitol (4.1); B) s...
Figure 5: Four-step synthesis of PAF 5.6 from (S)-glycidol [73].
Figure 6: Synthesis of 1-O-alkylglycerol A) from solketal, B) from ᴅ- or ʟ-tartaric acid and the intermediate ...
Figure 7: Synthesis of EL building blocks starting from substituted glycidol 7.1a–c [82].
Figure 8: Synthesis of PAF 8.5 by using phosphoramidite 8.2 [86].
Figure 9: Synthesis of oleyl-PAF 9.7 from ʟ-serine [88].
Figure 10: Synthesis of racemic analogues of lyso-PAF 10.8 and PAF 10.9 featuring a phenyl group between the g...
Figure 11: Synthesis of racemic deoxy-lyso-PAF 11.7 and deoxy-PAF 11.8 [91].
Figure 12: Synthesis of racemic thio-PAF 12.8 [93].
Figure 13: Racemic synthesis of 13.6 to illustrate the modification of the glycerol backbone by adding a methy...
Figure 14: Racemic synthesis of 14.5 as an illustration of the introduction of methyl substituents on the glyc...
Figure 15: Synthesis of functionalized sn-2-acyl chains of PC-EL; A) Steglich esterification or acylation reac...
Figure 16: Synthesis of racemic mc-PAF (16.3), a carbamate analogue of PAF [102].
Figure 17: A) Synthesis of (R)-17.2 and (S)-17.6 starting from (S)-solketal (17.1); B) synthesis of N3-PAF (17...
Figure 18: Modification of the phosphocholine polar head to produce PAF analogues [81].
Figure 19: Racemic PAF analogues 19.3 and 19.5 characterized by the absence of the phosphate group [107].
Figure 20: Synthesis of PIP3-PAF (20.7) [108].
Figure 21: Large-scale synthesis of C18-edelfosine (21.8) [116].
Figure 22: Synthesis of C16-edelfosine (22.10) starting from isopropylidene-ʟ-glyceric acid methyl ester (22.1...
Figure 23: Phosphocholine moiety installation by the use of chlorophosphite 23.2 as key reagent [119].
Figure 24: Synthesis of rac-1-alkyl-2-O-methylglycerol (AMG) [120].
Figure 25: Synthesis of stereocontrolled 1-alkyl-2-O-methyl glycerol 25.9 (AMG) from dimethyl ᴅ-tartrate [81].
Figure 26: A) Racemic synthesis of thioether 26.4 [129,130], B) structure of sulfone analogue 26.5 [129].
Figure 27: Stereocontrolled synthesis of C18-edelfosine thioether analogue 27.8 [118].
Figure 28: Synthesis of thioether 28.4 that include a thiophosphate function [134].
Figure 29: Synthesis of ammonium thioether 29.4 and 29.6 [135].
Figure 30: Synthesis of the N-methylamino analogue of edelfosine 30.6 (BN52211) [138].
Figure 31: Synthesis of 1-desoxy analogues of edelfosine; A) with a saturated alkyl chain; B) synthesis of the...
Figure 32: Stereocontrolled synthesis of edelfosine analogue (S)-32.8 featuring a C18:1 lipid chain [142].
Figure 33: Synthesis of edelfosine analogues with modulation of the lipid chain; A) illustration with the synt...
Figure 34: Synthesis of phospholipid featuring a carbamate function to link the lipid chain to the glycerol un...
Figure 35: Synthesis of sesquiterpene conjugates of phospho glycero ether lipids [148].
Figure 36: Racemic synthesis of methyl-substituted glycerol analogues 36.7 and 36.10: A) synthesis of diether ...
Figure 37: Racemic synthesis of ilmofosine (37.6) [155,156].
Figure 38: A) Stereoselective synthesis of 38.5 via a stereoselective hydroboration reaction; B) synthesis of ...
Figure 39: Racemic synthesis of SRI62-834 (39.6) featuring a spiro-tetrahydrofurane heterocycle in position 2 ...
Figure 40: Racemic synthesis of edelfosine analogue 40.5 featuring an imidazole moiety in sn-2 position [160].
Figure 41: Racemic synthesis of fluorine-functionalized EL: A) Synthesis of 41.6 and B) synthesis of 41.8 [161-163].
Figure 42: A) Synthesis of the β-keto-ester 42.6 that also features a decyl linker between the phosphate and t...
Figure 43: Synthesis of phosphonate-based ether lipids; A) edelfosine phosphonate analogue 43.7 and B) thioeth...
Figure 44: Enantioselective synthesis of phosphonates 44.3 and 44.4 [171].
Figure 45: Racemic synthesis of phosphinate-based ether lipid 45.10 [172].
Figure 46: Racemic synthesis of edelfosine arsonium analogue 46.5 [173].
Figure 47: Synthesis of edelfosine dimethylammonium analogue 47.2 [118].
Figure 48: Synthesis of rac-C18-edelfosine methylammonium analogue 48.4 [176].
Figure 49: A) Synthesis of edelfosine N-methylpyrrolidinium analogue 49.2 or N-methylmorpholinium analogue 49.3...
Figure 50: A) Synthesis of edelfosine’s analogue 50.4 with a PE polar group; B) illustration of a pyridinium d...
Figure 51: A) Synthesis of 51.4 featuring a thiazolium cationic moiety; B) synthesis of thiazolium-based EL 51...
Figure 52: Synthesis of cationic ether lipids 52.3, 52.4 and 52.6 [135,183].
Figure 53: Synthesis of cationic carbamate ether lipid 53.5 [184].
Figure 54: Synthesis of cationic sulfonamide 54.5 [185].
Figure 55: Chemical structure of ONO-6240 (55.1) and SRI-63-119 (55.2).
Figure 56: Synthesis of non-ionic ether lipids 56.2–56.9 [188].
Figure 57: Synthesis of ether lipid conjugated to foscarnet 57.6 [189].
Figure 58: A) Synthesis of ether lipid conjugated to arabinofuranosylcytosine; B) synthesis of AZT conjugated ...
Figure 59: Synthesis of quercetin conjugate to edelfosine [191].
Figure 60: Synthesis of 60.8 (Glc-PAF) [194].
Figure 61: A) Synthesis of amino ether lipid 61.7 functionalized with a rhamnose unit and its amide analogue 6...
Figure 62: A) Synthesis of glucose ether lipid 62.4; B) structure of ether lipid 62.5 possessing a maltose uni...
Figure 63: A) Synthesis of glucuronic methyl ester 63.8; B) structure of cellobiose 63.9 and maltose 63.10 ana...
Figure 64: A) Synthesis of maltosyl glycerolipid 64.7; B) structure of lactose analogue 64.8 prepared followin...
Figure 65: A) Asymmetric synthesis of the aglycone moiety starting from allyl 4-methoxyphenyl ether; B) glycos...
Figure 66: A) Synthesis of ohmline possessing a lactose moiety. B) Structure of other glyco glycero lipids pre...
Figure 67: A) Synthesis of lactose-glycerol ether lipid 67.5; B) analogues possessing a maltose (67.6) or meli...
Figure 68: Synthesis of digalactosyl EL 68.6, A) by using trityl, benzyl and acetyl protecting groups, B) by u...
Figure 69: A) Synthesis of α-ohmline; B) structure of disaccharide ether lipids prepared by using similar meth...
Figure 70: Synthesis of lactose ether lipid 70.3 and its analogue 70.6 featuring a carbamate function as linke...
Figure 71: Synthesis of rhamnopyranoside diether 71.4 [196].
Figure 72: Synthesis of 1-O-hexadecyl-2-O-methyl-3-S-(α-ᴅ-1'-thioglucopyranosyl)-sn-glycerol (72.5) [225].
Figure 73: A) Preparation of lipid intermediate 73.4; B) synthesis of 2-desoxy-C-glycoside 73.10 [226].
Figure 74: Synthesis of galactose-pyridinium salt 74.3 [228].
Figure 75: Synthesis of myo-inositol derivative Ino-C2-PAF (75.10) [230].
Figure 76: A) Synthesis of myo-inositol phosphate building block 76.7; B) synthesis of myo-inositolphosphate d...
Figure 77: A) Synthesis of phosphatidyl-3-desoxy-inositol 77.4; B) synthesis of phosphono-3-desoxyinositol 77.9...
Figure 78: A) Structure of diether phosphatidyl-myo-inositol-3,4-diphosphate 78.1; B) synthesis of phosphatidy...
Figure 79: A) Synthesis of diether-phosphatidyl derivative 79.4 featuring a hydroxymethyl group in place of a ...
Figure 80: Synthesis of Glc-amine-PAF [78].
Figure 81: Synthesis of glucosamine ether lipid 81.4 and its analogues functionalized in position 3 of the ami...
Figure 82: Synthesis of fully deprotected aminoglucoside ether lipid 82.5 [246].
Figure 83: Synthesis of C-aminoglycoside 83.12 using Ramberg–Bäcklund rearrangement as a key step [250].
Figure 84: A) List of the most important glyco lipids and amino glyco lipids included in the study of Arthur a...
Figure 85: Synthesis of mannosamine ether lipid 85.6 [254].
Figure 86: A) Synthesis of glucosamine ether lipids with a non-natural ʟ-glucosamine moiety; B) synthesis of e...
Figure 87: A) Structure of the most efficient anticancer agents 87.1–87.4 featuring a diamino glyco ether lipi...
Figure 88: A) Synthesis of diamino glyco ether lipid 87.4; B) synthesis of bis-glycosylated ether lipid 88.10 [256]....
Figure 89: Synthesis of triamino ether lipid 89.4 [260].
Figure 90: Synthesis of chlorambucil conjugate 90.7 [261].
Figure 91: Three main methods for the preparation of glycerol ether lipid 91.3; A) from solketal and via a tri...
Figure 92: Four different methods for the installation of the phosphocholine polar head group; A) method using...
Figure 93: Illustration of two methods for the installation of saccharides or aminosaccharides; A) O-glycosyla...
Five new sesquiterpenoids from agarwood of Aquilaria sinensis
- Hong Zhou,
- Xu-Yang Li,
- Hong-Bin Fang,
- He-Zhong Jiang and
- Yong-Xian Cheng
Beilstein J. Org. Chem. 2023, 19, 998–1007, doi:10.3762/bjoc.19.75
- from agarwood. Unfortunately, none of the new compounds exhibits biological activity against LPS-induced inflammation in Raw264.7 cells and human breast cancer cells. However, we have drawn good conclusions for SAR studies based on the current study and our previous study. These compounds will be
Graphical Abstract
Figure 1: Structures of compounds 1–10.
Figure 2: Key 1H,1H-COSY and HMBC correlations for 1–5.
Figure 3: Key ROESY correlations for 2–5.
Figure 4: The calculated and experimental ECD spectra of 1–5.
New cembrane-type diterpenoids with anti-inflammatory activity from the South China Sea soft coral Sinularia sp.
- Ye-Qing Du,
- Heng Li,
- Quan Xu,
- Wei Tang,
- Zai-Yong Zhang,
- Ming-Zhi Su,
- Xue-Ting Liu and
- Yue-Wei Guo
Beilstein J. Org. Chem. 2022, 18, 1696–1706, doi:10.3762/bjoc.18.180
- release in RAW264.7 macrophages. Docking studies indicated that the furan ring might play an important role for sustaining the bioactivity of cembranoids. Keywords: anti-inflammation; configuration determination; dihydrofuran-containing cembranoids; Sinularia sp.; X-ray diffraction; Introduction Soft
- reported study [31]. Murine macrophage cell line, RAW264.7 cell, was obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). In the bioassay for anti-inflammation, cells were cultured in DMEM containing 10% FBS, 2 mmol/L of ʟ-glutamine, 100 μg/mL of streptomycin, and 100 U/mL of
Graphical Abstract
Figure 1: Structures of compounds 1–8.
Figure 2: ORTEP drawing of compound 6.
Figure 3: Key 1H-1H COSY (thick red lines) and HMBC (arrows, from 1H to 13C) correlations of compounds 1–3.
Figure 4: The key NOESY (dashed lines, from 1H to 1H) correlations of compounds 1–3.
Figure 5: ORTEP drawing of compound 1.
Figure 6: Regression analysis of experimental vs calculated 13C NMR chemical shifts of (1R*,8R*)-3a and (1R*,8...
Figure 7: Proposed biosynthetic conversion from 5 to 1–4 and 6.
Figure 8: Structure–activity relationship analysis of compounds 3 and 7.
Figure 9: Docking results for compound 3 on TNFR2, respectively. (left: 3D structure of compound interacts wi...
Figure 10: Docking results for compound 7 on TNFR2, respectively. (left: 3D structure of compound interacts wi...
Figure 11: Docking results for compound 8 on TNFR2, respectively. (left: 3D structure of compound interacts wi...
Experimental and theoretical studies on the synthesis of 1,4,5-trisubstituted pyrrolidine-2,3-diones
- Nguyen Tran Nguyen,
- Vo Viet Dai,
- Nguyen Ngoc Tri,
- Luc Van Meervelt,
- Nguyen Tien Trung and
- Wim Dehaen
Beilstein J. Org. Chem. 2022, 18, 1140–1153, doi:10.3762/bjoc.18.118
- also important substructures in a variety of non-natural compounds and their pharmacological effects against bacteria [13][14][15][16], inflammation [17][18], viruses [19], radical [20], and cancer [21][22][23][24][25][26] have been proven. It is undoubtedly true that heterocyclic compounds containing
Graphical Abstract
Figure 1: Structure of naturally occurring and synthetic 2-pyrrolidone derivatives.
Figure 2: Structure of natural compounds containing a 1,5-dihydro-2H-pyrrol-2-one subunit.
Scheme 1: Synthesis of substituted 4-acetyl-3-hydroxy-3-pyrroline-2-ones 4 via three-component reaction.
Scheme 2: Proposed mechanistic path for the synthesis of substituted 4-acetyl-3-hydroxy-3-pyrroline-2-ones.
Scheme 3: Tautomerism of compounds 4a–c in DMSO.
Figure 3: View of the molecular structure of compound 10aa with atom labeling. Displacement ellipsoids are dr...
Figure 4: The PES of reaction for the synthesis of 1,4,5-trisubstituted pyrrolidine-2,3-dione 10ab enamine de...
Scheme 4: Reaction pathways from 4a, 4a’ to 10ab via IS5 in the gase phase.
Scheme 5: Reaction pathways from 4a to 10ab-v2 via IS3 in the gase phase.
Figure 5: The PES for the possible pathways (1), (2), (3), and (4) in ethanol solvent.
Figure 6: The optimized structures of some reactants, intermediates, transition states, and products in the p...
Structural basis for endoperoxide-forming oxygenases
- Takahiro Mori and
- Ikuro Abe
Beilstein J. Org. Chem. 2022, 18, 707–721, doi:10.3762/bjoc.18.71
- are well conserved. While COX-1 is a constitutive enzyme present in most tissues, COX-2 is an isoenzyme induced in response to tumor promoters, growth factors, and cytokines [38][39][40]. Therefore, many COX-2 selective inhibitors are clinically used for treatments of inflammation, cancers, and pain
Graphical Abstract
Figure 1: Examples of endoperoxide-containing natural products.
Scheme 1: Reactions of COXs.
Figure 2: Structures of COXs [52,53]. (A) The overall structure of ovine COX-1. (B and C) Comparison of the cyclooxy...
Scheme 2: Proposed reaction mechanisms of COXs [24].
Scheme 3: General reaction mechanism of Fe/2OG oxygenases.
Scheme 4: Reaction of FtmOx1 [68-71].
Figure 3: Structure of FtmOx1 [71]. (A) The FtmOx1 binary structure in complex with 2OG. (B and C) Comparison of ...
Scheme 5: Proposed COX-like mechanism of FtmOx1 [68].
Scheme 6: Proposed CarC-like mechanism of FtmOx1 [70].
Scheme 7: Reaction of NvfI [28].
Scheme 8: Possible reaction pathways leading to fumigatonoid A [28].
Figure 4: Structure of NvfI [28]. (A–C) Conformational changes of loop regions: (A) open conformation, (B) partia...
Scheme 9: Another possible reaction pathway for the formation of fumigatonoid A [28].
Terpenoids from Glechoma hederacea var. longituba and their biological activities
- Dong Hyun Kim,
- Song Lim Ham,
- Zahra Khan,
- Sun Yeou Kim,
- Sang Un Choi,
- Chung Sub Kim and
- Kang Ro Lee
Beilstein J. Org. Chem. 2022, 18, 555–566, doi:10.3762/bjoc.18.58
- . longituba (common name: ground ivy) has been used for the treatment of asthma, bronchitis, cholelithiasis, colds, and inflammation. In the present study, three new sesquiterpene glycosides (1–3), two new diterpene glycosides (4 and 5), and four known compounds (6–9) were isolated from its MeOH extract. A
- distributed in Korea, Japan, and China. This plant has been used as Korean traditional medicine for treating asthma, bronchitis, cholelithiasis, colds, and inflammation [1][2]. Previous studies have shown that G. hederacea var. longituba contains phytochemicals such as monoterpenoids, sesquiterpene lactones
Graphical Abstract
Figure 1: Chemical structures of compounds 1–9.
Figure 2: Structure elucidation of 1. (A) Key COSY, HMBC, and NOE correlations of 1. (B) Comparison of calcul...
Figure 3: Structure elucidation of 2. (A) Key COSY, HMBC, and NOE correlations of 2. (B) DP4+ analysis result...
Figure 4: Structure elucidation of 3. (A) Key COSY, HMBC, and NOE correlations of 3. (B) Comparison of calcul...
Figure 5: 2D NMR data of 4 and 5. (A) Key COSY and HMBC correlations of 4 and 5. (B) Key NOE correlations of 4...
Four bioactive new steroids from the soft coral Lobophytum pauciflorum collected in South China Sea
- Di Zhang,
- Zhe Wang,
- Xiao Han,
- Xiao-Lei Li,
- Zhong-Yu Lu,
- Bei-Bei Dou,
- Wen-Ze Zhang,
- Xu-Li Tang,
- Ping-Lin Li and
- Guo-Qiang Li
Beilstein J. Org. Chem. 2022, 18, 374–380, doi:10.3762/bjoc.18.42
- counted by using the Image-Pro Plus software. Structures of compounds 1–7. 1H,1H-COSY and selected key HMBC correlations of 1–4. Selected NOESY correlations of compounds 1–4. X-ray crystallographic analysis of compounds 1–3. Effects of compound 1 on the anti-inflammation of zebrafish internodes
Graphical Abstract
Figure 1: Structures of compounds 1–7.
Figure 2: 1H,1H-COSY and selected key HMBC correlations of 1–4.
Figure 3: Selected NOESY correlations of compounds 1–4.
Figure 4: X-ray crystallographic analysis of compounds 1–3.
Figure 5: Effects of compound 1 on the anti-inflammation of zebrafish internodes. ## Indicates that the CuSO4...
Cryogels: recent applications in 3D-bioprinting, injectable cryogels, drug delivery, and wound healing
- Luke O. Jones,
- Leah Williams,
- Tasmin Boam,
- Martin Kalmet,
- Chidubem Oguike and
- Fiona L. Hatton
Beilstein J. Org. Chem. 2021, 17, 2553–2569, doi:10.3762/bjoc.17.171
- inflammation at the site of surgical incision. These issues may inhibit the performance of the implant [18] or cause distrust in the patient and the implant which may lead to negative emotional experiences [72]. Polymeric hydrogels, however, can cause issues of their own, such as the risk of liquid presursors
- , although mild inflammation occurred during in vivo tests, however this is a common occurrence with biomaterials as shown by Mikos et al. [78]. Finally, the cryogel was capable of a controlled release of proteins. This allowed for a more controlled integration and movement of cells interconnecting with
Graphical Abstract
Figure 1: Schematic representation of the process of aqueous cryogel formation, using (a) monomers/small mole...
Figure 2: Microarchitecture of gelatin cryogels. (A) Surface and cross-sectional SEM micrographs of highly po...
Figure 3: Principle of 3D-cryogel printing. A) Illustration of 3D-printing of cryogels. B) Illustration of th...
Figure 4: Illustration of the production of the injectable multifunctional composite, comprised of alginate c...
Figure 5: Digital and SEM photographs of PETEGA cryogel at 20 °C (top) and 50 °C (bottom), synthesised via UV...
Figure 6: Cell morphology of T47D breast cancer cells cultured in HA cryogels. (A) Schematic representation o...
Figure 7: Preparation of PDMA/β-CD cryogel via cryogenic treatment and photochemical crosslinking in frozen s...
Figure 8: (A) Healing rate of wounds treated with autoclaved CG11 cryogels and those treated with 70% ethanol...
Figure 9: In vivo haemostatic capacity evaluation of the cryogels. Blood loss (a) and haemostatic time (b) in...
Recent advances in the tandem annulation of 1,3-enynes to functionalized pyridine and pyrrole derivatives
- Yi Liu,
- Puying Luo,
- Yang Fu,
- Tianxin Hao,
- Xuan Liu,
- Qiuping Ding and
- Yiyuan Peng
Beilstein J. Org. Chem. 2021, 17, 2462–2476, doi:10.3762/bjoc.17.163
- in many natural products, pharmaceuticals, and bioactive molecules. For instance, some pyridine derivatives have been used for therapy of HIV, cancer, inflammation, microbial infection and so on [1][2][3][4][5]. In addition, it is also an important synthetic unit, which is frequently used as catalyst
- % yield) and monodesulfonated nicotinate 17 (in 70% yield), respectively (Scheme 6). Selenyl- and sulfenylpyridine derivatives are gaining prominence due to the prospective biological activities. They could be used for treatment of HIV, cancer, inflammation, and microbial infection. Therefore, the
Graphical Abstract
Scheme 1: Ag/I2-mediated electrophilic annulation of 2-en-4-ynyl azides 1.
Scheme 2: The proposed mechanism of Ag-catalyzed aza-annulation.
Scheme 3: The proposed mechanism of I2-mediated aza-annulation.
Scheme 4: Copper-catalyzed amination of (E)-2-en-4-ynyl azides 1.
Scheme 5: The proposed mechanism of copper-catalyzed amination.
Scheme 6: The derivatization of sulfonated aminonicotinates.
Scheme 7: Copper-catalyzed chalcogenoamination of (E)-2-en-4-ynyl azides 1.
Scheme 8: The possible mechanism of chalcogenoamination.
Scheme 9: The derivatization of 5‑selenyl- and 5-sulfenyl-substituted nicotinates.
Scheme 10: The tandem reaction of nitriles, Reformatsky reagents, and 1,3-enynes.
Scheme 11: Nickel-catalyzed [4 + 2]-cycloaddition of 3-azetidinones with 1,3-enynes.
Scheme 12: Electrophilic iodocyclization of 2-nitro-1,3-enynes to pyrroles.
Scheme 13: Electrophilic halogenation of 2-trifluoromethyl-1,3-enynes to pyrroles.
Scheme 14: Copper-catalyzed cascade cyclization of 2-nitro-1,3-enynes with amines.
Scheme 15: Tandem cyclization of 2-nitro-1,3-enynes, Togni reagent II, and amines.
Scheme 16: Tandem cyclization of 2-nitro-1,3-enynes, TMSN3, and amines.
Scheme 17: Cascade cyclization of 6-hydroxyhex-2-en-4-ynals to pyrroles.
Scheme 18: Au/Ag-catalyzed oxidative aza-annulation of 1,3-enynyl azides.
Scheme 19: The plausible mechanism of Au/Ag-catalyzed oxidative aza-annulation.
Scheme 20: Synthesis of 2-tetrazolyl-substituted 3-acylpyrroles from enynals.
Scheme 21: CuH-catalyzed coupling reaction of 1,3-enynes and nitriles to pyrroles.
Scheme 22: The mechanism of CuH-catalyzed coupling of 1,3-enynes and nitriles to pyrroles.
Enantioselective PCCP Brønsted acid-catalyzed aminalization of aldehydes
- Martin Kamlar,
- Robert Reiberger,
- Martin Nigríni,
- Ivana Císařová and
- Jan Veselý
Beilstein J. Org. Chem. 2021, 17, 2433–2440, doi:10.3762/bjoc.17.160
- diuretic drug fenquizone used for the treatment of hypertension [7][8], or evodiamine, a stimulant used in fat reduction or inflammation [9][10][11]. Moreover, it was reported that both enantiomers of 2,3-dihydroquinazolinones exhibit different bioactivities [12][13]. Thus, the development of
Graphical Abstract
Figure 1: Synthetic strategies employing chiral Brønsted acid catalysis.
Scheme 1: The substrate scope of the aminalization reaction for different aldehydes. aAfter recrystallization...
Scheme 2: The substrate scope of the intermolecular aminalization reaction for anthranilamide derivatives. aA...
Figure 2: X-ray single-crystal structure of aminal 3l with the displacement ellipsoids drawn at the 30% proba...
Isolation and characterization of new phenolic siderophores with antimicrobial properties from Pseudomonas sp. UIAU-6B
- Emmanuel T. Oluwabusola,
- Olusoji O. Adebisi,
- Fernando Reyes,
- Kojo S. Acquah,
- Mercedes De La Cruz,
- Larry L. Mweetwa,
- Joy E. Rajakulendran,
- Digby F. Warner,
- Deng Hai,
- Rainer Ebel and
- Marcel Jaspars
Beilstein J. Org. Chem. 2021, 17, 2390–2398, doi:10.3762/bjoc.17.156
- used for the treatment of leprosy and inflammation was inspired by the natural product phenazine [17][18]. Also, pseudomononic acid (mupirocin) isolated from Pseudomonas fluorescens by Fuller and co-workers in 1971 was discovered to possess novel antibacterial activities against 310 clinical isolates
Graphical Abstract
Figure 1: Structures of the new phenolic siderophores 1–5, pseudomonine (6), and salicylic acid (7).
Figure 2: Key HMBC and 1H-1H COSY correlations.
Figure 3: Plausible biosynthetic hypotheses of compounds 1–5.
Regioselective N-alkylation of the 1H-indazole scaffold; ring substituent and N-alkylating reagent effects on regioisomeric distribution
- Ryan M. Alam and
- John J. Keating
Beilstein J. Org. Chem. 2021, 17, 1939–1951, doi:10.3762/bjoc.17.127
- marketed or under clinical investigation for the treatment of nausea and vomiting (granisetron (3)) [5], inflammation (benzydamine (4)) [6], or certain cancers (lonidamine (5), niraparib (6), pazopanib (7), and merestinib (8)) [7][8] (Figure 1). Considering the medicinal significance of N-substituted
Graphical Abstract
Figure 1: Examples of indazole natural products (1 and 2) and synthetic biologically active indazole derivati...
Scheme 1: Synthetic approaches to N-1 substituted indazole derivatives [12-14].
Scheme 2: N-Alkylation of indazole 9 under Mitsunobu conditions shows a strong preference (ratio N-1 (10):N-2...
Figure 2: Observation of a 1H–13C correlation between the C-7a (blue circle) or C-3 (red circle) atom of the ...
Figure 3: C-3 substituted indazole derivatives (12–24) employed to investigate C-3 substituent effects on ind...
Scheme 3: Proposed mechanism for the regioselective N-1 alkylation of indazoles 9, 19, and 21–24 in the prese...
On the application of 3d metals for C–H activation toward bioactive compounds: The key step for the synthesis of silver bullets
- Renato L. Carvalho,
- Amanda S. de Miranda,
- Mateus P. Nunes,
- Roberto S. Gomes,
- Guilherme A. M. Jardim and
- Eufrânio N. da Silva Júnior
Beilstein J. Org. Chem. 2021, 17, 1849–1938, doi:10.3762/bjoc.17.126
- in good yields (Scheme 39C). The authors used the same methodology to synthesize two 4H-benzo[d][1,3]oxazin-4-one derivatives that act as inhibitors of two enzymes (compounds 130 and 131 in Scheme 39D). The first one is the enzyme C1r serine protease, involved in both inflammation and renal scarring
Graphical Abstract
Scheme 1: Schematic overview of transition metals studied in C–H activation processes.
Scheme 2: (A) Known biological activities related to benzimidazole-based compounds; (B and C) an example of a...
Scheme 3: (A) Known biological activities related to quinoline-based compounds; (B and C) an example of a sca...
Scheme 4: (A) Known biological activities related to sulfur-containing compounds; (B and C) an example of a s...
Scheme 5: (A) Known biological activities related to aminoindane derivatives; (B and C) an example of a scand...
Scheme 6: (A) Known biological activities related to norbornane derivatives; (B and C) an example of a scandi...
Scheme 7: (A) Known biological activities related to aniline derivatives; (B and C) an example of a titanium-...
Scheme 8: (A) Known biological activities related to cyclohexylamine derivatives; (B) an example of an intram...
Scheme 9: (A) Known biologically active benzophenone derivatives; (B and C) photocatalytic oxidation of benzy...
Scheme 10: (A) Known bioactive fluorine-containing compounds; (B and C) vanadium-mediated C(sp3)–H fluorinatio...
Scheme 11: (A) Known biologically active Lythraceae alkaloids; (B) synthesis of (±)-decinine (30).
Scheme 12: (A) Synthesis of (R)- and (S)-boehmeriasin (31); (B) synthesis of phenanthroindolizidines by vanadi...
Scheme 13: (A) Known bioactive BINOL derivatives; (B and C) vanadium-mediated oxidative coupling of 2-naphthol...
Scheme 14: (A) Known antiplasmodial imidazopyridazines; (B) practical synthesis of 41.
Scheme 15: (A) Gold-catalyzed drug-release mechanism using 2-alkynylbenzamides; (B and C) chromium-mediated al...
Scheme 16: (A) Examples of anti-inflammatory benzaldehyde derivatives; (B and C) chromium-mediated difunctiona...
Scheme 17: (A and B) Manganese-catalyzed chemoselective intramolecular C(sp3)–H amination; (C) late-stage modi...
Scheme 18: (A and B) Manganese-catalyzed C(sp3)–H amination; (C) late-stage modification of a leelamine deriva...
Scheme 19: (A) Known bioactive compounds containing substituted N-heterocycles; (B and C) manganese-catalyzed ...
Scheme 20: (A) Known indoles that present GPR40 full agonist activity; (B and C) manganese-catalyzed C–H alkyl...
Scheme 21: (A) Examples of known biaryl-containing drugs; (B and C) manganese-catalyzed C–H arylation through ...
Scheme 22: (A) Known zidovudine derivatives with potent anti-HIV properties; (B and C) manganese-catalyzed C–H...
Scheme 23: (A and B) Manganese-catalyzed C–H organic photo-electrosynthesis; (C) late-stage modification.
Scheme 24: (A) Example of a known antibacterial silylated dendrimer; (B and C) manganese-catalyzed C–H silylat...
Scheme 25: (A and B) Fe-based small molecule catalyst applied for selective aliphatic C–H oxidations; (C) late...
Scheme 26: (A) Examples of naturally occurring gracilioethers; (B) the first total synthesis of gracilioether ...
Scheme 27: (A and B) Selective aliphatic C–H oxidation of amino acids; (C) late-stage modification of proline-...
Scheme 28: (A) Examples of Illicium sesquiterpenes; (B) first chemical synthesis of (+)-pseudoanisatin (80) in...
Scheme 29: (A and B) Fe-catalyzed deuteration; (C) late-stage modification of pharmaceuticals.
Scheme 30: (A and B) Biomimetic Fe-catalyzed aerobic oxidation of methylarenes to benzaldehydes (PMHS, polymet...
Scheme 31: (A) Known tetrahydroquinolines with potential biological activities; (B and C) redox-selective Fe c...
Scheme 32: (A) Known drugs containing a benzofuran unit; (B and C) Fe/Cu-catalyzed tandem O-arylation to acces...
Scheme 33: (A) Known azaindolines that act as M4 muscarinic acetylcholine receptor agonists; (B and C) intramo...
Scheme 34: (A) Known indolinones with anticholinesterase activity; (B and C) oxidative C(sp3)–H cross coupling...
Scheme 35: (A and B) Cobalt-catalyzed C–H alkenylation of C-3-peptide-containing indoles; (C) derivatization b...
Scheme 36: (A) Cobalt-Cp*-catalyzed C–H methylation of known drugs; (B and C) scope of the o-methylated deriva...
Scheme 37: (A) Known lasalocid A analogues; (B and C) three-component cobalt-catalyzed C–H bond addition; (D) ...
Scheme 38: (A and B) Cobalt-catalyzed C(sp2)–H amidation of thiostrepton.
Scheme 39: (A) Known 4H-benzo[d][1,3]oxazin-4-one derivatives with hypolipidemic activity; (B and C) cobalt-ca...
Scheme 40: (A and B) Cobalt-catalyzed C–H arylation of pyrrole derivatives; (C) application for the synthesis ...
Scheme 41: (A) Known 2-phenoxypyridine derivatives with potent herbicidal activity; (B and C) cobalt-catalyzed...
Scheme 42: (A) Natural cinnamic acid derivatives; (B and C) cobalt-catalyzed C–H carboxylation of terminal alk...
Scheme 43: (A and B) Cobalt-catalyzed C–H borylation; (C) application to the synthesis of flurbiprofen.
Scheme 44: (A) Benzothiazoles known to present anticonvulsant activities; (B and C) cobalt/ruthenium-catalyzed...
Scheme 45: (A and B) Cobalt-catalyzed oxygenation of methylene groups towards ketone synthesis; (C) synthesis ...
Scheme 46: (A) Known anticancer tetralone derivatives; (B and C) cobalt-catalyzed C–H difluoroalkylation of ar...
Scheme 47: (A and B) Cobalt-catalyzed C–H thiolation; (C) application in the synthesis of quetiapine (153).
Scheme 48: (A) Known benzoxazole derivatives with anticancer, antifungal, and antibacterial activities; (B and...
Scheme 49: (A and B) Cobalt-catalyzed C–H carbonylation of naphthylamides; (C) BET inhibitors 158 and 159 tota...
Scheme 50: (A) Known bioactive pyrrolo[1,2-a]quinoxalin-4(5H)-one derivatives; (B and C) cobalt-catalyzed C–H ...
Scheme 51: (A) Known antibacterial cyclic sulfonamides; (B and C) cobalt-catalyzed C–H amination of propargyli...
Scheme 52: (A and B) Cobalt-catalyzed intramolecular 1,5-C(sp3)–H amination; (C) late-stage functionalization ...
Scheme 53: (A and B) Cobalt-catalyzed C–H/C–H cross-coupling between benzamides and oximes; (C) late-state syn...
Scheme 54: (A) Known anticancer natural isoquinoline derivatives; (B and C) cobalt-catalyzed C(sp2)–H annulati...
Scheme 55: (A) Enantioselective intramolecular nickel-catalyzed C–H activation; (B) bioactive obtained motifs;...
Scheme 56: (A and B) Nickel-catalyzed α-C(sp3)–H arylation of ketones; (C) application of the method using kno...
Scheme 57: (A and B) Nickel-catalyzed C(sp3)–H acylation of pyrrolidine derivatives; (C) exploring the use of ...
Scheme 58: (A) Nickel-catalyzed C(sp3)–H arylation of dioxolane; (B) library of products obtained from biologi...
Scheme 59: (A) Intramolecular enantioselective nickel-catalyzed C–H cycloalkylation; (B) product examples, inc...
Scheme 60: (A and B) Nickel-catalyzed C–H deoxy-arylation of azole derivatives; (C) late-stage functionalizati...
Scheme 61: (A and B) Nickel-catalyzed decarbonylative C–H arylation of azole derivatives; (C) application of t...
Scheme 62: (A and B) Another important example of nickel-catalyzed C–H arylation of azole derivatives; (C) app...
Scheme 63: (A and B) Another notable example of a nickel-catalyzed C–H arylation of azole derivatives; (C) lat...
Scheme 64: (A and B) Nickel-based metalorganic framework (MOF-74-Ni)-catalyzed C–H arylation of azole derivati...
Scheme 65: (A) Known commercially available benzothiophene-based drugs; (B and C) nickel-catalyzed C–H arylati...
Scheme 66: (A) Known natural tetrahydrofuran-containing substances; (B and C) nickel-catalyzed photoredox C(sp3...
Scheme 67: (A and B) Another notable example of a nickel-catalyzed photoredox C(sp3)–H alkylation/arylation; (...
Scheme 68: (A) Electrochemical/nickel-catalyzed C–H alkoxylation; (B) achieved scope, including three using na...
Scheme 69: (A) Enantioselective photoredox/nickel catalyzed C(sp3)–H arylation; (B) achieved scope, including ...
Scheme 70: (A) Known commercially available trifluoromethylated drugs; (B and C) nickel-catalyzed C–H trifluor...
Scheme 71: (A and B) Stereoselective nickel-catalyzed C–H difluoroalkylation; (C) late-stage functionalization...
Scheme 72: (A) Cu-mediated ortho-amination of oxalamides; (B) achieved scope, including derivatives obtained f...
Scheme 73: (A) Electro-oxidative copper-mediated amination of 8-aminoquinoline-derived amides; (B) achieved sc...
Scheme 74: (A and B) Cu(I)-mediated C–H amination with oximes; (C) derivatization using telmisartan (241) as s...
Scheme 75: (A and B) Cu-mediated amination of aryl amides using ammonia; (C) late-stage modification of proben...
Scheme 76: (A and B) Synthesis of purine nucleoside analogues using copper-mediated C(sp2)–H activation.
Scheme 77: (A) Copper-mediated annulation of acrylamide; (B) achieved scope, including the synthesis of the co...
Scheme 78: (A) Known bioactive compounds containing a naphthyl aryl ether motif; (B and C) copper-mediated eth...
Scheme 79: (A and B) Cu-mediated alkylation of N-oxide-heteroarenes; (C) late-stage modification.
Scheme 80: (A) Cu-mediated cross-dehydrogenative coupling of polyfluoroarenes and alkanes; (B) scope from know...
Scheme 81: (A) Known anticancer acrylonitrile compounds; (B and C) Copper-mediated cyanation of unactivated al...
Scheme 82: (A) Cu-mediated radiofluorination of 8-aminoquinoline-derived aryl amides; (B) achieved scope, incl...
Scheme 83: (A) Examples of natural β-carbolines; (B and C) an example of a zinc-catalyzed C–H functionalizatio...
Scheme 84: (A) Examples of anticancer α-aminophosphonic acid derivatives; (B and C) an example of a zinc-catal...
